Clinical trials: Cyclophosphamide
Breast Cancer
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070278
- Testing
- cyclophosphamide, epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-small Cell Lung Cancer (NSCLC) Stage III
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a single dose of intravenous cyclophosphamide (CPA)…
- Trial name
- FINGERPRINT (NCT01731587)
- Testing
- Biological: MUC1 peptide specific immunotherapy, Cyclophosphamide (CPA)
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).
- Trial name
- NCT00149214
- Testing
- pemetrexed, cyclophosphamide, doxorubicin
- Where
- 11 sites in Germany, Italy and 2 more
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Chronic Lymphocytic Leukemia
Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project
FCR (fludarabine, cyclophosphamide, rituximab) combination is currently accepted as the gold standard in treatment of younger and physically fit CLL patients.
- Trial name
- Q-lite (NCT02156726)
- Testing
- low-dose FCR
- Where
- 7 sites in Czechia
- Volunteers
- 200 people
- Sponsor
- Czech CLL Study Group
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have…
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00002649
- Testing
- aldesleukin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- National Cancer Institute (NCI)
Neuromyelitis Optica
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a demyelinating and degenerative disorder of the CNS affecting vision and spinal cord function. This disease is rare compared to Multiple Sclerosis (MS), but it is devastating and often leads to…
- Trial name
- SCT-NMO (NCT01339455)
- Testing
- AHSCT
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of Calgary
Acute Myeloid Leukemia
Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
The primary goal of the study is to show that the treatment-related mortality of allogeneic hematopoietic stem cell transplantation an be significantly reduced by using a combination of 8 Gy total-body-irradiation and fludarabine…
- Trial name
- NCT00150878
- Testing
- Conditioning therapy
- Where
- Germany
- Volunteers
- 198 people
- Sponsor
- University Hospital Carl Gustav Carus
Soft Tissue Sarcoma
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy.
- Trial name
- NCT04776525
- Testing
- Ifosfamide, Doxorubicin
- Where
- 2 sites in Norway
- Volunteers
- 49 people
- Sponsor
- Oslo University Hospital
Soft Tissue Sarcoma
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma
To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.
- Trial name
- NCT01102608
- Testing
- Ifosfamide
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Solid Tumor
A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients.
- Trial name
- NCT05971589
- Testing
- LM103
- Volunteers
- 5 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
HER2-positive Breast Cancer
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis.
- Trial name
- TaxDHER2 (NCT06711068)
- Where
- China
- Volunteers
- 8,077 people
- Sponsor
- Shu Wang
Pemphigus Vulgaris
Comparing DCP and DAP for Pemphigus Vulgaris
What's the study about? This study focused on comparing two different treatments for pemphigus vulgaris, a skin condition caused when body's immune system works against itself.
- Trial name
- DCP;DAP (NCT06846255)
- Testing
- Dexamethasone Cyclophosphamide Pulse therapy, Dexamethasone Azathioprine Pulse therapy
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Jinnah Postgraduate Medical Centre
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05097443
- Testing
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Shandong Provincial Hospital
Leukemia, Lymphoma
High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003116
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Case Comprehensive Cancer Center
Hematologic Neoplasms
Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units
The administration of high-dose chemotherapy followed by the infusion of blood or bone marrow stem cells (stem cell transplantation) from a matched donor has become standard treatment for patients with high-risk or relapsed…
- Trial name
- NCT02504047
- Testing
- T-Cell replete haplo-transplant
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Follicular Lymphoma ( FL)
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
This study intends to conduct a prospective, multicenter, open-label, randomized controlled clinical trial to systematically evaluate the efficacy and safety of the orelabrutinib plus obinutuzumab and lenalidomide (RO2) regimen…
- Trial name
- NCT07719855
- Testing
- Orelabrutinib, obinutuzumab, Lenalidomide
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Ruijin Hospital
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma
- Trial name
- NCT00354835
- Testing
- Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride
- Where
- 226 sites in United States, Australia and 4 more
- Volunteers
- 481 people
- Sponsor
- Children's Oncology Group
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Ovarian Cancer, Fallopian Tube Cancer
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- DC-Ova (NCT00478452)
- Testing
- DC-Ova, DC Ova with Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania